Incyte Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
INCY Nasdaq 2836 www.incyte.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Incyte Corporation

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Oct 1st, 2026 1:33 pm
INCY or TECH: Which Is the Better Value Stock Right Now? - Sep 30th, 2026 8:40 am
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy - Sep 28th, 2026 8:45 am
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss - Sep 28th, 2026 8:03 am
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment - Sep 28th, 2026 6:38 am
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva - Sep 25th, 2026 5:00 pm
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill - Sep 25th, 2026 12:43 pm
Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data - Sep 24th, 2026 12:14 pm
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data - Sep 23rd, 2026 7:15 pm
6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewards - Sep 23rd, 2026 6:28 am
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Sep 22nd, 2026 10:53 pm
Dow Jones Tech Titan Amazon Eyes Buy Point Amid Battle With Key Support Level - Sep 22nd, 2026 11:26 am
Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says - Sep 22nd, 2026 9:45 am
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio - Sep 22nd, 2026 6:30 am
FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week - Sep 21st, 2026 5:06 am
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia - Sep 20th, 2026 2:00 pm
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target - Sep 19th, 2026 8:02 pm
Robinhood Soars, SpaceX Orbits Entry: Five Stocks Near Buy Points - Sep 19th, 2026 6:00 am
IBD Stock Of The Day Eyes Buy Points As Investors Dig Into Its Pipeline - Sep 18th, 2026 10:52 am
Dow Jones Futures: After S&P 500, Nasdaq Rebound, What's Next? Moderna, AMD, SpaceX Flash Buy Signals. - Sep 18th, 2026 6:02 am